New Job Opportunity

Entos Pharmaceuticals Secures $198.5M Partnership with Canada and Alberta for Biomanufacturing Expansion

Entos Pharmaceuticals (Entos), announced a $62 million investment from the Government of Canada. This further leverages the previously announced $15.5 million awarded to Entos from the Government of Alberta. The $77.5 million total investment will support a $198.5 million project to create a state-of-the-art R&D centre and GMP biomanufacturing facility in Edmonton, Alberta, Canada. The project builds on the significant partnership Entos has with global healthcare leader Eli Lilly & Company to research, develop, and commercialize nucleic acid products targeting the central and peripheral nervous system, as well as other partnerships with companies such as Oisin Biotechnologies, OncoSenX, and Aegis Life, and to advance its therapeutic pipeline for cancer and rare genetic diseases like Congenital Lipodystrophy, Stargardt Disease and Duchenne Muscular Dystrophy. As a hub for next-generation therapeutics, the facility aims to foster collaborations between Entos, Canadian academic institutions, and its industry partners. This effort will build expertise and knowledge to enhance Canada's life sciences sector, strengthen Canada’s position in the global biopharmaceutical market, and attract international investments, partnerships, and talent. “Our government is protecting the Canadians of tomorrow by making the necessary investments today. By supporting the construction of this state-of-the-art facility in Edmonton, we are strengthening our capacity to produce cutting-edge therapeutics and vaccines, which will better equip Canada in responding to future health emergencies. We are resolved to foster innovation and secure a resilient life sciences ecosystem that will keep Canadians safe for generations to come.” The Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry. “This new Edmonton facility means that Canada will get a greater capacity to develop lifesaving medicines right here in Canada. It strengthens our domestic biomanufacturing capacity which will lead to improved health outcomes for Canadians.” The Honourable Mark Holland, Minister of Health. “Alberta’s life sciences sector is booming, and this new manufacturing facility and R&D centre from Entos will only add to the momentum. Alberta is home to many world-class researchers developing potentially ground-breaking new medicines and treatments that will literally save lives. This investment will support Alberta’s efforts to become the most innovative jurisdictions in Canada.” The Honourable Nate Glubish, Minister of Technology and Innovation for Alberta. “This extraordinary investment from the federal and provincial governments ensures Alberta—and the University of Alberta—continues to play a leading role in strengthening Canada’s biomanufacturing and pharmaceutical sector. This new research facility will advance research and innovation and improve health outcomes for people in Canada and worldwide,” said Bill Flanagan, President and Vice-Chancellor, University of Alberta. “We are thrilled to receive this investment, which will enable us to build a cutting-edge GMP biomanufacturing facility and innovative R&D centre in Edmonton, Alberta, Canada,” said John Lewis, CEO, Entos Pharmaceuticals. “It will help us develop, scale up, produce, and commercialize Fusogenix PLV therapeutics to address critical health needs and fill gaps in Canada’s domestic manufacturing capacity.”

Syngene Acquires US Biologics Site for mAbs Manufacturing

Syngene International Limited ('Syngene'), a global contract research, development, and manufacturing organization (CRDMO) announced the acquisition of its first biologics site in the USA – fitted with multiple monoclonal antibody (mAbs) manufacturing lines. Syngene's investment in its first facility in the United States marks a strategic commitment to the US market, with significant benefits for the local economy and the broader life sciences industry. The facility is expected to create jobs, stimulate local economic activity, and strengthen domestic biologics manufacturing capabilities, while also contributing to pharmaceutical innovation and supply chain resilience. This investment highlights the potential for deeper economic collaboration between India and the United States, fostering sustained economic growth and advancing the shared goal of bolstering critical healthcare infrastructure. Peter Bains, CEO Designate, Syngene International Ltd., said, "With one of the largest biologics R&D teams and commercial scale manufacturing capabilities in both India and the USA, we now offer a compelling and flexible solution for global pharma and biotech customers. This investment will enable Syngene to cater to growing client requirements in an expanding market. It will also provide clients, access to collective service capability of multiple geographic sites, scientists and experience." Alex Del Priore, Senior Vice President – Development & Manufacturing Services, Syngene International Ltd., said, "This facility is a significant milestone for Syngene and comes in response to growing client demand in the United States, the fastest-growing biologics market. It strengthens our offering for animal health clients looking for USDA approval for their products. Most importantly, it increases the options we can offer our global customers, providing commercial-scale biologics manufacturing capabilities across our global network and will be underpinned by existing key client projects." "The investment will be synergistic with expected additional process development work that will be executed in India while manufacturing can be done in the US. The investment will be fully funded through internal accruals and cash. The Company will continue to maintain a robust balance sheet, a low debt profile, and a comfortable safety margin for debt covenants post this investment. As we ramp up utilization, we expect asset turnover to grow to 1x in less than 5 years, with EBIT margins expected to be in line with the Company average from FY30 and positively contribute to bottom line. The acquisition will not materially impact the current financial guidance given for fiscal year 2024 - 2025. In the short term, we expect minor dilution of operating margins as a result of costs to be incurred in this facility," added Deepak Jain, CFO, Syngene International Ltd.

ASHP Partners with ShiftRx to Strengthen Pharmacy Workforce

ASHP (American Society of Health-System Pharmacists) announced a partnership with ShiftRx, the first-in-market pharmacy staffing and workforce management platform, to further their shared commitment to uplifting the pharmacy workforce and delivering high-quality patient care across all healthcare settings. "ASHP has long been committed to advancing the professional growth of the pharmacy profession and ensuring patients have access to needed pharmacist care," said Kathy Pawlicki, BSPharm, MS, RPh, FASHP, ASHP vice president of business development and strategy. "We are thrilled to work with ShiftRx to offer innovative workforce solutions, expanded career development opportunities, and essential support for pharmacy professionals and employers across all patient care settings. By working together, we can support the needs of the pharmacy workforce and ensure the profession thrives." Rather than offering short-term fixes, ShiftRx's platform and innovative technology provide sustainable staffing solutions with a provider-first focus. By automating administrative tasks such as sourcing, credentialing, onboarding, scheduling, and billing, ShiftRx allows pharmacists and technicians to prioritize patient care and pursue professional growth opportunities. "Temporary work only provides a temporary fix, and we're aiming to completely solve the burnout crisis among healthcare providers – starting with pharmacy," said Autumn-Kyoko Cushman, CEO of ShiftRx. "We want pharmacy professionals to have the ability to leverage their license for additional income, gain exposure to new clinical workflows, upskill their careers, and ultimately, provide them expanded career opportunities. We're excited to work with ASHP to enable healthcare providers to focus on what they do best — patient care."

Axplora to strengthen its leading position in ADC Manufacturing

Axplora, a global leader in API small molecule and ADC (antibody-drug conjugate) manufacturing, is strengthening its leading position in the commercial manufacturing of ADCs with the launch of a cutting-edge payload manufacturing workshop at its Le Mans site (France). This expansion, which is part of the France 2030 program, builds on Axplora’s proven commercial track record, supplying 40% of the world’s marketed ADCs, and 50% of FDA-approved ADCs. The new state-of-the-art facility reinforces Axplora’s commitment to deliver high-quality clinical and commercial-scale solutions for ADC development and manufacturing. Axplora continues to partner with leading innovative pharmaceutical companies developing the next generation of targeted therapies in oncology, benefitting thousands of patients worldwide. “This expansion is a bold step forward in our mission to support clients at every stage of ADC development and manufacturing,” stated Arul Ramadurai, Chief Commercial Officer. “By combining state-of-the-art payload manufacturing with our proven expertise in purification and bioconjugation, we’re enabling pharmaceutical innovators to accelerate drug development and deliver transformative treatments to patients faster.” “With this investment, Axplora is strengthening its position as a global leader in the development and manufacturing of antibody-drug conjugates,” said Rachel de Luca, Site Director, Le Mans. “The addition of this new payload manufacturing asset demonstrates our dedication to equipping clients with the cutting-edge tools and capabilities needed to develop the next generation of life-saving therapies.”

CordenPharma Expands Peptide Platform, Creating 300+ New Jobs

CordenPharma is pleased to share significant progress on its growth initiatives with a >€1 billion strategic investment in peptide development and manufacturing. The company's ambitious expansion plans are set to propel its Peptide Platform business beyond the €1 billion sales milestone by 2028, reinforcing CordenPharma's position as a market leader in integrated supply of small to large-scale services from APIs to Drug Products, for both Injectable and Oral Peptides. As part of this strategy, CordenPharma has finalized plans to establish a state-of-the-art peptide manufacturing facility in Switzerland located at Getec Park in Muttenz, just 8 km outside Basel – a major biotech and pharma hub within Europe. This >€500 million investment will feature multiple manufacturing lines capable of supporting small, medium, and large-scale peptide production with small- to large-scale Solid Phase Peptide Synthesis (SPPS) reactors for GLP-1 and non-GLP-1 peptide projects – with a total SPPS reactor capacity of more than 5,000 L. The new state-of-the-art facility will feature advanced automation, cutting-edge digitalization, and innovative peptide production technologies, ensuring compliance with the most stringent regulations, including BLA requirements. With the main construction and qualification phase taking place between 2025 and 2027 and start of commercial activities to begin in the first half of 2028, the company is proud to generate over 300 new jobs, contributing to economic growth and innovation of the region. Dr. Michael Quirmbach, President & CEO of CordenPharma Group comments: "We are excited to announce the construction of a state-of-the-art manufacturing plant just outside Basel, Switzerland, within one of the leading pharma and biotech hubs in Europe. The new facility is designed to deliver flexible and efficient peptide manufacturing to meet the growing demand of innovative peptide medicines for our customers and ultimately, patients." Judith Charpentier, Co-Head Flagship Fund and Head of Healthcare at Astorg comments: "CordenPharma's bold expansion reflects its leadership in addressing the growing demand for peptide manufacturing. As a long-term investor, we are fully committed to supporting this growth, combining industrial excellence with strategic investment to strengthen CordenPharma's position as a leading global CDMO. Ultimately, this expansion contributes to expanding access to those life-saving peptide-based medicines for patients."

Bionova Opens Fremont Process Development and Pilot Plant

Bionova Scientific, an Asahi Kasei company and boutique commercial-scale biologics contract development and manufacturing organization (CDMO), has announced the opening of a new facility in Fremont, California. The 55,000 sq. ft. process development and pilot plant will significantly expand the company’s ability to advance early-stage biologics assets to first-in-human trials and facilitate the future expansion of its manufacturing capacity. Bionova hosted a ribbon-cutting ceremony attended by approximately 150 industry and community leaders to mark the occasion. Darren Head, Chairman & President; Jesse McCool, Ph.D., Chief Scientific Officer; and James Glover II, Chief Operating Officer, were joined by The Honorable Raj Salwan, Mayor of the City of Fremont. Representatives were also in attendance from the Office of Congressman Ro Khanna and Congressman Eric Swallwell; the Office of State Senator Dr. Aisha Wahab; the Office of the Alameda County Assessor Phong La; and Cindy Bonior, CEO of the Fremont Chamber of Commerce. At the event, Fremont Mayor Raj Salwan commented, “Fremont has long been a leader in biopharmaceutical and medical device manufacturing. Being home to over 100 biomedical companies, Fremont has adopted the industry slogan of being the City where BioMed goes to scale. Having operated its entire existence in Fremont, Bionova is unique in being a 100% homegrown success story, and their growth has been remarkable. Fremont wholeheartedly congratulates Bionova on their new facility and expansion in our community and looks forward to our continued partnership for many years to come.” “Bionova’s team of bioprocess experts has proven itself as a valuable partner for clients seeking to overcome challenging CMC issues, especially with complex modalities,” said Michelle Chen, Senior Vice President for Process Development and Manufacturing at Bionova. “With this new facility, all of our pre-GMP activities are co-located and integrated under one roof. We already see meaningful technical and efficiency gains as our PD teams can facilitate seamless technology transfer by scaling and training simultaneously.”

Eli Lilly Expands U.S. Manufacturing with $50B Investment, Creating 13,000 Jobs

Eli Lilly and Company announced at a press conference in Washington, D.C., plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical manufacturing sites in the United States. This brings the company's total U.S. capital expansion commitments to more than $50 billion since 2020. Three of the future U.S. sites announced today will focus on manufacturing active pharmaceutical ingredients (API), reshoring critical capabilities of small molecule chemical synthesis and further strengthening Lilly's supply chain. The fourth location will extend the company's global parenteral manufacturing network for future injectable therapies. "Lilly's optimism about the potential of our pipeline across therapeutic areas – cardiometabolic health, oncology, immunology and neuroscience – drives our unprecedented commitment to our domestic manufacturing build-out. Our confidence positions us to help reinvigorate domestic manufacturing, which will benefit hard-working American families and increase exports of medicines made in the U.S.A.," said David A. Ricks, Lilly chair and CEO. "This bold move reflects our commitment to stay ahead of anticipated demand for safe, high-quality, FDA-approved medicines of the future." At these four new sites, Lilly expects to create more than 3,000 jobs for highly skilled workers, including engineers, scientists, operations personnel and lab technicians. Additionally, the company anticipates that it could create nearly 10,000 construction jobs during the development of the sites. "To deliver on our big bets on next-generation modalities like small molecules, biologics and nucleic acid therapies, Lilly is investing in the state-of-the-art manufacturing infrastructure needed to deliver tomorrow's safe and reliable medicines," said Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations. "We are not just building facilities. We are creating a future where American innovation leads the world in pharmaceutical manufacturing, requiring a highly skilled workforce prepared to shape the future of health care. This is a significant step for our company, our communities and the patients we serve." Expected additional economic benefits of these new sites to the selected communities include increased local spending, tax revenue, economic diversification, improved infrastructure, population growth, and training and development opportunities.

Aster DM Healthcare Expands in Kerala, Creating 4,200 Jobs

Aster DM Healthcare, one of India’s leading integrated healthcare providers, has reinforced its deep-rooted commitment to Kerala with a strategic vision for expansion and long-term investment. Aligned with the state's efforts to attract and facilitate high-impact investments under the ‘Invest Kerala Global Summit’ initiative held in Kochi, Dr. Azad Moopen, Founder and Chairman, and Mr. Anoop Moopen, Director at Aster DM Healthcare met Kerala Chief Minister Shri Pinarayi Vijayan and Shri P Rajeev, Minister of Law, Industries, and Coir to discuss the current healthcare landscape and explore opportunities for growth and innovation. As part of the engagement, Aster has said that it plans to invest around ₹850cr in the next 3 years towards scaling up its infrastructure, medical services, and employment generation in the region. This commitment builds on the ₹500cr Aster has already invested in Kerala during the last 3 years, further solidifying its leadership in the state’s healthcare landscape. Looking ahead, Aster has an aggressive investment plan in Kerala that will result in a significant increase in bed capacity, bringing the total number of beds in the state to 3,453 by FY27. Aster currently operates seven hospitals in Kerala, with a total capacity of 2,635 beds, contributing to 53% of the company’s India revenue (9M FY25). Aster DM Healthcare’s expansion in the state will be driven by two greenfield projects that are coming up namely Aster Capital Trivandrum with a 454-bed facility and Aster MIMS Kasargod with 264 beds. The flagship hospital Aster Medcity will expand to 962 beds by FY27 as well. In Q3FY25, 100 beds were added to Aster Medcity’s existing capacity, further cementing Aster’s leadership in Kerala’s healthcare sector. Participating in the Invest Kerala Global Summit 2025, Dr. Azad Moopen, Founder and Chairman, Aster DM Healthcare, said, “Kerala has always been at the heart of Aster’s journey, and our commitment to the state is stronger than ever. We are delighted to reaffirm our long-term vision to expand our footprint, bringing world-class healthcare closer to the people of Kerala while fostering employment and medical excellence in the region. The ‘Invest Kerala Global Summit’ is a pivotal initiative that underscores the state’s potential as a hub for high-impact investments, and we are proud to be a part of this transformative journey. We plan to invest an additional ₹850cr in the next 3 years to further strengthen Kerala’s healthcare landscape. Our expansion plans reflect our unwavering belief in Kerala’s potential as a leader in healthcare innovation and accessibility.” Mr. Anoop Moopen, Director, Aster DM Healthcare said, “Aster DM Healthcare has been a significant contributor in creating thousands of opportunities for skilled professionals in Kerala. Today, Aster provides direct employment to over 12700 professionals in Kerala, including thousands of doctors, nurses, and paramedical staff. With our expansion plans, we anticipate creating an additional 4200 jobs, further strengthening Kerala’s healthcare workforce and economy. Being part of the ‘Invest Kerala Global Summit’ reinforces our commitment to not only building infrastructure but also nurturing talent, empowering communities, and reinforcing Kerala’s reputation as a centre for medical excellence.”

Core Scientific Expands to Alabama, Adding Jobs and Investing $400M

Core Scientific Inc. , a leader in digital infrastructure for high-performance compute at scale, announced its expansion into Auburn, Alabama, with a new high-performance computing facility. “Auburn represents an exciting new chapter for Core Scientific as we establish our presence in Alabama,” said Adam Sullivan, Core Scientific CEO. “This facility is expected to play a key role in our high-performance computing strategy, and we are grateful for the strong partnership and support from local and state leaders, including Auburn city officials. We look forward to contributing to Auburn’s growing technology sector and strengthening the regional economy.” The Core Scientific Auburn data center, housed within the existing AUBix facility, will launch with a capacity of 16 megawatts and has potential for further expansion. Core Scientific is planning to make an initial investment of approximately $135 million in the facility, with total investment in the project expected to exceed $400 million, including substantial capital expenditures from future partners. In the process of becoming the operator of the Samford Avenue facility, Core Scientific has leased the building and is planning to execute an option to purchase. It has retained the facility’s 11 full-time employees as part of its commitment to the local workforce. The company plans to increase its team to a minimum of 20 full-time employees. “Alabama has long been a pro-business state, and Core Scientific’s investment in Auburn is a testament to our ability to attract cutting-edge technology companies,” said Alabama Governor Kay Ivey. “We are excited to support their growth and look forward to the economic benefits this project will bring to our state.” “Core Scientific’s expansion into Alabama highlights the state’s growing prominence in the technology and digital infrastructure sector,” said Alabama’s Secretary of Commerce, Ellen McNair. “This investment not only strengthens our state’s economy but also positions Alabama as a key player in the future of high-performance computing.” “We appreciate Core Scientific establishing a new operation here in Auburn as part of its national data center network,” said Auburn Mayor Ron Anders. “The company’s investment is evidence of the success of our recruitment of high-tech industries in collaboration with Auburn University. Our projections show that Core Scientific’s $400 million investment will result in a local tax generation of $1.5 million per year, supporting our schools and public services.”

Sodexo Expands Healthcare Technology Management with Advanced Facility in India

Sodexo India has inaugurated a new, state-of-the-art Healthcare Technology Management (HTM) facility in Kolkata, equipped with specialized labs to support the maintenance of up to 5 lakh medical devices. Featuring 6 specialized labs, supported by a dedicated team of more than 270 technical professionals and backed by an extensive network & partnerships with OEMs, this facility is designed to enhance the service efficiency for advanced testing, repair and maintenance capabilities across a range of biomedical equipments. With the new facility, Sodexo will ensure an impressive 99% uptime, delivering on its promise of reliable service and minimizing equipment downtime, providing the much-needed support to healthcare providers in for optimal delivery of health and care services across the state of West Bengal and widen the scope of operations across markets. The new facility will be covering 100% of the public health care set ups, namely government hospitals, small & medium diagnostics centers and medical colleges in Presidency region, Burdwan and Jalpaiguri. Additionally, it will enable Sodexo to scale up its HTM operations and support the expansion of biomedical equipment maintenance in other markets. Speaking about the new facility, Sharad Misra, Chief Operating Officer, Sodexo Health & Care, Said Our expansion of HTM operations in the state underscores our commitment to ensuring optimal performance of critical healthcare equipments and supporting the healthcare providers to improve patient care. Our expertise in digitalising end-to-end maintenance cycle of medical equipment (i.e. tagging, tracking, service, repair and maintenance), has helped healthcare providers to adapt a preventive approach to maintenance of medical equipment and assets, which is crucial to effective patient care. Our services, delivered by a group of technical experts, ensure equipment uptime to enable accurate and timely diagnosis to offer the right treatment. Our long-standing partnership with HITES has been a model operation for healthcare facilities combining infrastructure, digital enablement and technical expertise powered by Sodexo. With our new facility in West Bengal, serving HITES, our largest contract, we are strategically positioned to enhance our HTM operations and capture the growing market opportunities in the region and across the country. Sharad MisraCOO – Health & Care, Sodexo India State-of-the-Art Labs: Sodexo has established advanced repair labs and spare depots for improving equipment uptime. There are 6 specialized labs catering to a range of healthcare equipment and devices such as Electro-Technical lab, Pressure, Acceleration and Speed Lab, QA Testing Lab, Mass & Volume Lab, Thermal Lab, Inhouse Repair Lab and warehouse. An extensive vendor network and partnership with OEMs ensures availability of critical components with minimum turnaround time from its central warehouse. Paperless & Comprehensive Digital Solution: Sodexo’s HTM digital solution helps healthcare providers to instantly access inventory status, real-time updates on complaint, automatic scheduling as per regulations. Customizable digital MIS dashboard facilitates end-to-end service delivery with an overview of complete equipment lifecycle. Dedicated Technical Team: Sodexo’s on-site and central pool of experts are trained to handle all types of equipment. The new facility employs over 270+ technical staff including engineers, 80+ subject matter experts, health & safety certified experts for quality and excellence, supporting all audits and accreditation.